Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2023 / Apr / One Drop Is All It Takes
Omics Liquid biopsy Analytical science Precision medicine Technology and innovation Molecular Pathology

One Drop Is All It Takes

Could a new multi omics microsampling platform “Amazonize” healthcare?

By Jessica Allerton 04/24/2023 News 1 min read

Share

Looking to mine more health information from more people – and much more easily, researchers from Stanford University have developed a strategy that combines multi omic profiling from a series of blood samples with physiological measurements from wearable sensors (1). Rather than using traditional blood draws, the potential of the approach relies on the notion that a microsampling device and 10 μl of blood is all it takes to measure thousands of metabolites, lipids, cytokines, and proteins. Sound familiar?

“It’s Theranos that works,” quipped Michael Snyder – Stanford W. Ascherman Professor of Genetics at Stanford and corresponding author of the paper – according to an article in USA Today (2). But how does it work? Well, it relies on lab-based mass spec.

“Mass spectrometry has gotten much faster and more convenient, and we can now measure thousands of analytes in a small blood droplet,” says Snyder. “This analysis gives a much clearer picture of a patient’s immune function, inflammation, metabolic markers, and overall health.”

Indeed, the approach could allow scientists to ask interesting questions about the impact of lifestyle on health; for example, how the persistence of caffeine may correlate with sleep quality or how people respond to a nutrient shake. “Interestingly, some people had a proinflammatory response and others had an anti-inflammatory response to the exact same shake,” says Snyder, reminding us of some healthcare buzzwords – precision and personalized medicine. Snyder believes that, in addition to answering very interesting research questions, the strategy will open the door to more large-scale biomarker discovery, monitoring, and health profiling. As for the Stanford team, further studies are underway, including research into chronic fatigue syndrome.

As with any new technology, there is scope to evolve the strategy: “There will be additional improvements in stability and sensitivity, allowing the device to follow many more molecules,” says Snyder. But, while his team is busy working away, he wants diagnostic professionals to know this type of testing is coming. “It will be more powerful than what is measured in a physician’s office,” he says. “I believe that at-home testing will become common.”

Snyder concludes with a thought-provoking prediction: “Healthcare will be ‘Amazonized.’”

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. X Shen et al., Nat Biomed (2023). DOI: 10.1038/s41551-022-00999-8.
  2. USA Today News, “A geneticist studied one drop of his blood – and saw things he couldn’t from a vial of blood” (2023). Available at: https://rb.gy/c4my2

About the Author(s)

Jessica Allerton

Deputy Editor, The Pathologist

More Articles by Jessica Allerton

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Turning Tides
Omics
Turning Tides

January 9, 2024

3 min read

A new study shows evidence for sustained human-to-human transmission of mpox since 2016

“Pop” Goes the Sensor
Omics
“Pop” Goes the Sensor

January 19, 2022

1 min read

A new device could help scientists identify signs of arrhythmia, heart attack, and cardiac fibrosis

Improving Risk Stratification
Omics
Improving Risk Stratification

February 3, 2022

1 min read

Two genes have been identified that may be linked to prostate cancer outcomes

The Ultimate Vision for Rare Disease
Omics
The Ultimate Vision for Rare Disease

February 28, 2022

1 min read

Genomics and computational pathology can take rare disease diagnostics to the next level

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.